Marja Puurunen

3.4k total citations · 1 hit paper
45 papers, 2.0k citations indexed

About

Marja Puurunen is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Rheumatology. According to data from OpenAlex, Marja Puurunen has authored 45 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Cardiology and Cardiovascular Medicine, 12 papers in Internal Medicine and 9 papers in Rheumatology. Recurrent topics in Marja Puurunen's work include Atrial Fibrillation Management and Outcomes (14 papers), Antiplatelet Therapy and Cardiovascular Diseases (12 papers) and Venous Thromboembolism Diagnosis and Management (12 papers). Marja Puurunen is often cited by papers focused on Atrial Fibrillation Management and Outcomes (14 papers), Antiplatelet Therapy and Cardiovascular Diseases (12 papers) and Venous Thromboembolism Diagnosis and Management (12 papers). Marja Puurunen collaborates with scholars based in Finland, United States and United Kingdom. Marja Puurunen's co-authors include Outi Vaarala, Timo Palosuo, Matti Mänttäri, Vesa Manninen, Kimmo Aho, Kaija Javela, Leena Tenkanen, Aoife M. Brennan, William S. Denney and Pirjo Mustonen and has published in prestigious journals such as Circulation, Journal of the American College of Cardiology and PLoS ONE.

In The Last Decade

Marja Puurunen

45 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans

2019 280 citations Caroline Kurtz, Yves Millet et al. Science Translational Medicine profile →

Peers

Countries citing papers authored by Marja Puurunen

Since Specialization

Citations

This map shows the geographic impact of Marja Puurunen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marja Puurunen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marja Puurunen more than expected).

Fields of papers citing papers by Marja Puurunen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marja Puurunen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marja Puurunen. The network helps show where Marja Puurunen may publish in the future.

Co-authorship network of co-authors of Marja Puurunen

This figure shows the co-authorship network connecting the top 25 collaborators of Marja Puurunen. A scholar is included among the top collaborators of Marja Puurunen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marja Puurunen. Marja Puurunen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and safety of a synthetic biotic for treatment of phenylketonuria: a phase 2 clinical trial 2023 ·Nature Metabolism ·Jerry Vockley, Neal Sondheimer, Marja Puurunen, George A. Díaz, (unknown), Dorothy K. Grange, Cary O. Harding, Hope Northrup, John A. Phillips, (unknown), Janet A. Thomas, Roberto T. Zori, William S. Denney, Sharon L. Ernst, (unknown), (unknown), Caroline Kurtz, Aoife M. Brennan	41
2	Influence of Polymorphisms in CYP2C9 , VKORC1 , MDR1 and APOE Genes on the Warfarin Maintenance Dose in Brazilian Patients 2023 ·Pharmacogenomics ·(unknown), Karina Braga Gomes, Daniel Dias Ribeiro, Marja Puurunen, (unknown), (unknown), Manoel Otávio da Costa Rocha, Renan P. Souza, Maria Auxiliadora Parreiras Martins	1
3	Complications of the Low Phenylalanine Diet for Patients with Phenylketonuria and the Benefits of Increased Natural Protein 2022 ·Nutrients ·(unknown), (unknown), Marja Puurunen, Sharon L. Ernst	19
4	Development of a mechanistic model to predict synthetic biotic activity in healthy volunteers and patients with phenylketonuria 2021 ·Communications Biology ·Mark R. Charbonneau, William S. Denney, (unknown), (unknown), Mary Joan Castillo, Marja Puurunen, Aoife M. Brennan	13
5	Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study 2021 ·Nature Metabolism ·Marja Puurunen, Jerry Vockley, (unknown), Stephanie Sacharow, John A. Phillips, William S. Denney, Benjamin D. Goodlett, David A. Wagner, Larry Blankstein, Mary Joan Castillo, Mark R. Charbonneau, Vincent M. Isabella, (unknown), Richard J. Riese, Caroline Kurtz, Aoife M. Brennan	105
6	An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans breakdown → 2019 ·Science Translational Medicine ·Caroline Kurtz, Yves Millet, Marja Puurunen, Mylène Perreault, Mark R. Charbonneau, Vincent M. Isabella, Jonathan W. Kotula, (unknown), Yossi Dagon, William S. Denney, David A. Wagner, Kip A. West, (unknown), Aoife M. Brennan, Paul Miller	280
7	ASSOCIATION OF PLATELET AGGREGATION WITH ATRIAL FIBRILLATION: THE FRAMINGHAM OFFSPRING STUDY 2018 ·Journal of the American College of Cardiology ·Mayank Sardana, Shih‐Jen Hwang, Marja Puurunen, Geoffrey H. Tofler, Steven A. Lubitz, Emelia J. Benjamin, David D. McManus, Andrew D. Johnson	1
8	Platelet function as a risk factor for venous thromboembolism in the Framingham Heart Study 2017 ·Thrombosis Research ·Marja Puurunen, Shih‐Jen Hwang, Chris O’Donnell, Geoffrey H. Tofler, Andrew D. Johnson	14
9	Epidemiology of venous thromboembolism in the Framingham Heart Study 2016 ·Thrombosis Research ·Marja Puurunen, Philimon Gona, Martin G. Larson, Joanne M. Murabito, Jared W. Magnani, Christopher J. O’Donnell	87
10	Biomarkers for the prediction of venous thromboembolism in the community 2016 ·Thrombosis Research ·Marja Puurunen, Danielle Enserro, Vanessa Xanthakis, Martin G. Larson, Emelia J. Benjamin, Geoffrey H. Tofler, Kai C. Wollert, Christopher J. O’Donnell, Ramachandran S. Vasan	13
11	Renal Impairment and Prognosis of Patients with Atrial Fibrillation Undergoing Coronary Intervention - The AFCAS Trial 2015 ·PLoS ONE ·(unknown), Tuomas Kiviniemi, Marja Puurunen, Axel Schlitt, Andrea Rubboli, Antti Ylitalo, José Valencia, Gregory Y.H. Lip, Juhani Airaksinen	6
12	Impact of anaemia on clinical outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention: insights from the AFCAS registry 2014 ·BMJ Open ·Marja Puurunen, Tuomas Kiviniemi, Wail Nammas, Axel Schlitt, Andrea Rubboli, Kai Nyman, Pasi P. Karjalainen, Paulus Kirchhof, Gregory Y.H. Lip, Juhani Airaksinen	17
13	Performance of Bleeding Risk-Prediction Scores in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention 2014 ·The American Journal of Cardiology ·Tuomas Kiviniemi, Marja Puurunen, Axel Schlitt, Andrea Rubboli, Pasi P. Karjalainen, Saila Vikman, Matti Niemelä, (unknown), Gregory Y.H. Lip, Juhani Airaksinen	27
14	Type II antithrombin deficiency caused by a founder mutation Pro73Leu in the Finnish population: clinical picture 2013 ·Journal of Thrombosis and Haemostasis ·Marja Puurunen, Perttu Salo, (unknown), Kaija Javela, Markus Perola	32
15	Great discrepancy in antithrombin activity measured using five commercially available functional assays 2013 ·Thrombosis Research ·Kaija Javela, (unknown), Leena Hiltunen, Pirjo Mustonen, Marja Puurunen	21
16	Comparison of Additional Versus No Additional Heparin During Therapeutic Oral Anticoagulation in Patients Undergoing Percutaneous Coronary Intervention 2012 ·The American Journal of Cardiology ·Tuomas Kiviniemi, Pasi P. Karjalainen, Mikko Pietilä, Antti Ylitalo, Matti Niemelä, Saila Vikman, Marja Puurunen, Fausto Biancari, Juhani Airaksinen	16
17	Usefulness of Outpatient Bleeding Risk Index to Predict Bleeding Complications in Patients With Long-term Oral Anticoagulation Undergoing Coronary Stenting 2010 ·The American Journal of Cardiology ·Juhani Airaksinen, (unknown), Pekka Porela, Matti Niemelä, Saila Vikman, Marja Puurunen, (unknown), Fausto Biancari, Pasi P. Karjalainen	15
18	Are glycoprotein inhibitors safe during percutaneous coronary intervention in patients on chronic warfarin treatment? 2009 ·Thrombosis and Haemostasis ·(unknown), Pasi A. Karjalainen, Matti Niemelä, Saila Vikman, Kari Kervinen, Antti Ylitalo, Marja Puurunen, Pekka Porela, Kai Nyman, Susanna Hinkka‐Yli‐Salomäki, Juhani Airaksinen	16
19	Safety of percutaneous coronary intervention during uninterrupted oral anticoagulant treatment 2008 ·European Heart Journal ·Pasi P. Karjalainen, Saila Vikman, Mika Niemelä, Pekka Porela, Antti Ylitalo, (unknown), Marja Puurunen, (unknown), Kai Nyman, Tero Vahlberg, Juhani Airaksinen	70
20	Antibodies to prothrombin crossreact with plasminogen in patients developing myocardial infarction 1998 ·British Journal of Haematology ·Marja Puurunen, Matti Mänttäri, Vesa Manninen, (unknown), Outi Vaarala	27

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact